Your competent? doctor has already summarized this research right? I've got nothing on NDRIs. If your doctor is talking depression meds IT MEANS THEY ARE FUCKING INCOMPETENT IN GETTING YOU 100% RECOVERED!
- SSRIs
(31 posts to January 2013) Benefits and problems in here.
SSRI vs NDRI: Which Is Better for Post-Stroke Depression?
SAN FRANCISCO — The selective serotonin reuptake inhibitor (SSRI) fluoxetine and the norepinephrine-dopamine reuptake inhibitor (NDRI) bupropion are each effective for different psychiatric symptoms of post-stroke depression (PSD), new research suggests.
In a large retrospective cohort study with data for more than 100,000 patients with PSD, bupropion was associated with a significantly lower risk for suicidal ideation — the primary outcome — compared to treatment with fluoxetine.
However, for the secondary outcome of decreased demoralization and apathy, fluoxetine was the winner. (No 100% recovery protocols is the cause of demoralization! GET THERE!)
The results highlight the importance of customizing PSD treatment to the patient, said investigator Jaime Villa, an incoming first-year medical student at Reading Hospital, Tower Health System.
“For clinicians, the take-away message is that each of these antidepressants have a different effect on transmitters in the body,” Villa told Medscape Medical News. “So I’d say: focus on the symptoms and just treat each with the appropriate antidepressant.” The findings were presented May 17 at the American Psychiatric Association (APA) 2026 Annual Meeting.
Large Cohort
Depression is a common complication of stroke, affecting about 1 in 3 survivors, and is associated with poor recovery and increased morbidity. Most PSD cases occur within the first year post-stroke.
Fluoxetine is considered a first-line treatment for PSD, with both SSRIs and serotonin-norepinephrine reuptake inhibitors often prescribed for the condition. Caution has been urged for bupropion use in this population because it lowers the seizure threshold, and some studies have suggested a slightly higher risk for bleeding events.
The new retrospective cohort study aimed to address the lack of head-to-head data for secondary psychiatric outcomes between antidepressant classes.
“We wanted to look at the effect SSRIs and NDRIs had on the body for specific symptoms of depression,” Villa noted.
For the analysis, investigators included 2005-2025 data for 108,664 adult patients (mean age, 64 years; 59% women; 73% White) from the TriNetX Research Network database. All had been diagnosed with PSD within a year previously, with half receiving treatment with fluoxetine and the other half receiving bupropion.
Individualized Treatment Needed
Results showed a significantly lower suicidal ideation risk for the bupropion-treated group compared to the fluoxetine group (odds ratio [OR], 0.76; P < .05), as well as a lower percentage of recurrence (2.04% vs 2.66%, respectively).
However, bupropion was linked to greater increased risk for demoralization and apathy vs fluoxetine (OR, 1.54; P < .05), with a higher percentage of recurrence (0.13% vs 0.08%).
NDRIs increase the concentration of dopamine and norepinephrine and are known to regulate energy, motivation, and reward pathways, which Villa said could account for its efficacy for suicidal ideation prevention in patients with PSD.
Fluoxetine acts as a mood stabilizer and stress reliever, which makes it effective for such symptoms as apathy. However, it has a lower likelihood of affecting other neurotransmitters, including dopamine and norepinephrine, which may explain why it was less effective at preventing suicidal ideation, Villa added.
“These findings highlight differential psychiatric effects across antidepressant classes and underscore the importance of individualized treatment selection in PSD management,” he said.
The findings also underscore that clinicians have options depending on their patient's symptoms, he added.
Potentially Practice Changing?
The results offer some unexpected findings, said Charles S. Nguyen, MD, clinical professor of psychiatry at the University of California, Riverside, who was not part of the study.
“I always thought with bupropion, because it can lower the seizure threshold, maybe there’s a higher risk for seizures post-stroke. So I would not have thought that it would be a good choice to make” for this patient population, Nguyen told Medscape Medical News.
“We all knew that it could potentially be helpful, and after I look at this data showing it can help, I may be more inclined to consider it in my own practice in the future,” Nguyen added.
One question the research doesn’t answer, he noted, is whether there was an increased risk of stroke recurrence in the study participants.
Asked later about this concern, Villa said that while that outcome was not assessed in the current study, it would be an important topic to look into in the future.
No comments:
Post a Comment